Publication | Closed Access
Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients
42
Citations
27
References
2022
Year
In our cohort, the effectiveness and safety of galcanezumab were comparable with those reported in clinical trials, whereas a higher response rate was observed in the difficult-to-treat patient subset than that reported in trials. We provide real-world evidence of galcanezumab treatment benefits in Asian patients with migraine.
| Year | Citations | |
|---|---|---|
Page 1
Page 1